Last reviewed: May 12, 2026
Last updated: May 12, 2026
Written by:
Jay Hastings
,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
From the PlexusDx Education Hub, an independent side-by-side of two very different GLP-1 weight-management models: Noom and Ro. Browse all Peptides & GLP-1 education
Independent editorial comparison. PlexusDx has no commercial relationship with Ro, Noom, or their parent companies, and there are no affiliate links or compensation involved.
Noom and Ro often show up in the same search, but they start from different places — one built around a behavior-change app, the other around subscription telehealth. As of April 2026 the GLP-1 market holds dozens of options; this piece keeps to the two named here and the genetic variable neither measures.
Two starting points, one drug class
The clearest way to read Noom versus Ro is by origin. Both can connect you to GLP-1 medication, but they approach it from opposite ends — app-first behavior change on one side, telehealth-first prescribing on the other. Underneath, the pharmacology is the same class; the difference is packaging, oversight, and price.
Noom’s app-first approach
Noom (Noom, Inc.) built its name on an app-based behavior-change subscription, with medication offered as an add-on. Program structures, medication options, and pricing vary, so treat Noom’s official website as the source of truth for what is currently included.
Ro’s telehealth-first approach
Ro (Roman Health) runs as subscription telehealth: virtual clinical evaluation, provider-issued prescriptions, and either brand-name FDA-approved GLP-1 dispensing or compounded semaglutide and tirzepatide through licensed compounding-pharmacy pathways. Current program details live on Ro’s official website.
The pharmacology both share
Whatever the wrapper, both operate in the GLP-1 receptor agonist space. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide modulate appetite regulation, satiety signaling, and gastric emptying. The evidence — STEP (NEJM 2021), SURMOUNT (NEJM 2022), SURMOUNT-OSA (NEJM 2024) — attaches to the compound, not to the brand delivering it.
What each costs
Pricing spans a wide range across the market as of April 2026 — monthly totals of roughly $200 to $700+ including program fees, medication, and compounded dispensing where it applies. Because Noom and Ro each publish their own figures and change them over time, verify current pricing directly on each brand’s page rather than relying on a number quoted elsewhere.
The variable neither Noom nor Ro measures
Neither program reads the upstream genetics behind a GLP-1 response. Variants in FTO, GLP1R, MC4R, and TCF7L2 map baseline appetite, energy-balance, and glucose biology. They are pathway-level — they do not predict response to a specific compound, but they describe the terrain any GLP-1 medication works on.
PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Ahead of any protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including FTO, GLP1R, MC4R, and TCF7L2 variants that shape your metabolic baseline. That is the test before you invest approach — genetic context first, then an informed conversation with your provider.
Not affiliated: PlexusDx is not affiliated with Ro or Noom and holds no commercial relationship with the companies reviewed in this article.
Related reading on PlexusDx: GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone.
Disclaimer: This article is educational. PlexusDx is not affiliated with Ro or Noom and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols; this comparison covers approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.
Consider a third path: see the Weight Management Protocols, or start with the Precision Peptide Genetic Test to understand your GLP-1 pathway first.
Frequently Asked Questions
Is Noom or Ro the better choice?
Neither is objectively better; they are built on different models — Noom app-first with a medication add-on, Ro telehealth-first with prescribing. Fit depends on cost, coverage, medication options, and how much behavior-change support you want. Review each brand’s current details before deciding.
Do Noom and Ro prescribe the same medications?
Both operate in the GLP-1 receptor agonist space and can connect you to that class through telehealth. Differences fall in the dispensing pathway (branded versus compounded), subscription structure, and provider model. Neither program determines the underlying pharmacology, which belongs to the compound itself.
Can a genetic test tell me which program will work?
No. The Precision Peptide Genetic Test does not predict response to Noom, Ro, or any specific compound. It reads pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that describe baseline GLP-1 biology — upstream context that applies across every program regardless of brand.
Where does PlexusDx fit against Noom and Ro?
PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, paired with the Precision Peptide Genetic Test. The distinction is upstream genetic insight mapping FTO, GLP1R, and MC4R variants — context that Noom, Ro, and most other GLP-1 programs do not provide.
This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Hers vs Noom: Approach, Pricing, Compounded Pathway, and Genetics
Hers vs Noom: Approach, Pricing, Compounded Pathway, and Genetics